The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 32 | — | 20.1x | Below average | |
Growth | 54 | 4.9% | 5.6% | Near average | |
Quality | 3 | -1449.5% | 7.6% | Below average | |
Safety | 36 | 0.4x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Prime Medicine, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Prime Medicine, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analysts' outlook for Prime Medicine has shown quantitative stability in the average price target at $17.25, despite one analyst recently dropping coverage (a decrease in count from 6 to 5). The significant spread between the high estimate ($23) and the low estimate ($12) reflects a dispersion in expectations; however, all these targets remain substantially higher than the current trading price ($2.97), indicating a wide valuation gap inherent to the nature of the biotechnology sector.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.